HK1145342A1 - Prognosis prediction for melanoma cancer - Google Patents

Prognosis prediction for melanoma cancer

Info

Publication number
HK1145342A1
HK1145342A1 HK10111778.3A HK10111778A HK1145342A1 HK 1145342 A1 HK1145342 A1 HK 1145342A1 HK 10111778 A HK10111778 A HK 10111778A HK 1145342 A1 HK1145342 A1 HK 1145342A1
Authority
HK
Hong Kong
Prior art keywords
markers
cancer
prognostic
melanoma
prognosis
Prior art date
Application number
HK10111778.3A
Other languages
English (en)
Inventor
Michael Alan Black
Jonathan Cebon
Parry John Guilford
Thomas John
Original Assignee
Pacific Edge Biotechnology Ltd
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Edge Biotechnology Ltd, Ludwig Inst Cancer Res filed Critical Pacific Edge Biotechnology Ltd
Publication of HK1145342A1 publication Critical patent/HK1145342A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
HK10111778.3A 2007-05-24 2010-12-16 Prognosis prediction for melanoma cancer HK1145342A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ555363A NZ555363A (en) 2007-05-24 2007-05-24 Prognosis prediction for melanoma cancer
PCT/NZ2008/000118 WO2008143533A1 (en) 2007-05-24 2008-05-23 Prognosis prediction for melanoma cancer

Publications (1)

Publication Number Publication Date
HK1145342A1 true HK1145342A1 (en) 2011-04-15

Family

ID=40032133

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111778.3A HK1145342A1 (en) 2007-05-24 2010-12-16 Prognosis prediction for melanoma cancer

Country Status (17)

Country Link
US (3) US8822149B2 (xx)
EP (2) EP2158332B1 (xx)
JP (5) JP5943315B2 (xx)
CN (1) CN101743327B (xx)
AR (1) AR066725A1 (xx)
AU (1) AU2008253836B2 (xx)
CA (1) CA2725602A1 (xx)
CL (1) CL2008001517A1 (xx)
DK (2) DK2158332T3 (xx)
ES (2) ES2622858T3 (xx)
HK (1) HK1145342A1 (xx)
NZ (1) NZ555363A (xx)
PT (2) PT2158332T (xx)
SG (2) SG10201509568QA (xx)
TW (2) TWI582236B (xx)
UY (1) UY31105A1 (xx)
WO (1) WO2008143533A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
PL2140269T3 (pl) 2007-03-27 2014-07-31 Immunovia Ab Podpis białkowy/znaczniki do wykrywania gruczolakoraka
JP5683280B2 (ja) * 2011-01-04 2015-03-11 株式会社日立製作所 診療支援システム
CN102617734B (zh) * 2011-12-28 2013-09-04 暨南大学 抗FGF-2抗体Dab-2及其应用
US9336302B1 (en) 2012-07-20 2016-05-10 Zuci Realty Llc Insight and algorithmic clustering for automated synthesis
US9355105B2 (en) * 2012-12-19 2016-05-31 International Business Machines Corporation Indexing of large scale patient set
ES2947946T3 (es) 2013-03-14 2023-08-24 Castle Biosciences Inc Métodos para predecir el riesgo de metástasis en melanoma cutáneo
EP3292536B1 (en) * 2015-05-05 2024-04-03 RetInSight GmbH Computerized device and method for processing image data
WO2018009887A1 (en) * 2016-07-08 2018-01-11 University Of Hawaii Joint analysis of multiple high-dimensional data using sparse matrix approximations of rank-1
US11205103B2 (en) 2016-12-09 2021-12-21 The Research Foundation for the State University Semisupervised autoencoder for sentiment analysis
US10692605B2 (en) * 2018-01-08 2020-06-23 International Business Machines Corporation Library screening for cancer probability
TW202018727A (zh) 2018-11-09 2020-05-16 財團法人工業技術研究院 整體式學習預測方法與系統
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112200391B (zh) * 2020-11-17 2023-07-04 国网陕西省电力公司经济技术研究院 基于k-近邻互信息特征简化的配电网边缘侧负荷预测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074330A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074430A2 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008043018A1 (en) * 2006-10-04 2008-04-10 Dana-Farber Cancer Institute, Inc. Tumor immunity

Also Published As

Publication number Publication date
JP2017079765A (ja) 2017-05-18
AR066725A1 (es) 2009-09-09
CL2008001517A1 (es) 2009-01-09
EP3176270B1 (en) 2020-07-08
JP2015061528A (ja) 2015-04-02
PT3176270T (pt) 2020-10-08
TWI582236B (zh) 2017-05-11
US20100136553A1 (en) 2010-06-03
NZ555363A (en) 2009-11-27
TWI609967B (zh) 2018-01-01
AU2008253836B2 (en) 2014-11-27
PT2158332T (pt) 2017-04-26
UY31105A1 (es) 2009-01-05
EP2158332A4 (en) 2011-01-05
EP2158332A1 (en) 2010-03-03
US8822149B2 (en) 2014-09-02
SG10201912289SA (en) 2020-02-27
SG10201509568QA (en) 2015-12-30
EP2158332B1 (en) 2017-01-18
CA2725602A1 (en) 2008-11-27
ES2821300T3 (es) 2021-04-26
US20170107583A1 (en) 2017-04-20
US20150031578A1 (en) 2015-01-29
EP3176270A1 (en) 2017-06-07
DK2158332T3 (en) 2017-05-01
ES2622858T3 (es) 2017-07-07
AU2008253836A1 (en) 2008-11-27
CN101743327A (zh) 2010-06-16
TW201500553A (zh) 2015-01-01
WO2008143533A1 (en) 2008-11-27
JP2010527604A (ja) 2010-08-19
JP6404304B2 (ja) 2018-10-10
US9534258B2 (en) 2017-01-03
JP2019004907A (ja) 2019-01-17
TW200914623A (en) 2009-04-01
JP5943315B2 (ja) 2016-07-05
JP2020150949A (ja) 2020-09-24
CN101743327B (zh) 2013-04-24
DK3176270T3 (da) 2020-10-12
US10266902B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
HK1145342A1 (en) Prognosis prediction for melanoma cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
EP2392678A3 (en) Prognosis prediction for colorectal cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
MX2013005762A (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201171367A1 (ru) Винилиндазолильные соединения
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
IN2012DN01979A (xx)
ATE525484T1 (de) Slco1b3-genotyp

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210525